NBTX

Business Context and Reporting Period

Company: Nanobiotix S.A.
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: Nanobiotix is a late-stage clinical biotechnology company developing physics-based nanotechnology therapies, primarily focused on its lead product candidate NBTXR3 (JNJ-1900), a radioenhancer designed to improve radiation therapy outcomes for solid tumors. The company operates under a global licensing agreement with Janssen Pharmaceutica NV (Janssen) for the development and commercialization of NBTXR3, excluding the Asia Licensing Territory (also assigned to Janssen in late 2023).
Key Operational Update: In October 2024, Nanobiotix and Janssen began transferring global sponsorship of the pivotal Phase 3 NANORAY-312 clinical trial to Janssen. A subsequent amendment signed on March 17, 2025, further reduced Nanobiotix's funding obligations for this trial, extending the company's cash runway into mid-2026.

Key Financial Metrics (Year Ended December 31, 2024)

Note: The negative revenue in 2024 is primarily due to a non-cash accounting adjustment related to the transfer of the NANORAY-312 trial sponsorship to Janssen, which resulted in a contract modification under IFRS 15.

Material Changes vs. Prior Period

• Revenue Volatility: Total revenues swung from €36.2 million in 2023 to negative €7.2 million in 2024. This was driven by a €23.4 million negative catch-up adjustment related to the Janssen contract modification (replacing R&D service obligations with a funding obligation), partially offset by €7.7 million in sales of clinical products and services to Janssen and €3.3 million in research tax credits.
• Increased Net Loss: Net loss widened to €68.1 million from €39.7 million in 2023, largely reflecting the negative revenue impact and continued investment in R&D (€40.5 million) and SG&A (€20.5 million).
• Cash Position: Cash and cash equivalents decreased by €25.5 million to €49.7 million, reflecting operating cash outflows and financing activities, despite the receipt of a €20 million milestone payment from Janssen in May 2024.
• Debt Structure: Total financial liabilities remained relatively stable at €50.9 million. The company holds significant debt from the European Investment Bank (EIB), including principal, accrued interest, and royalty-based obligations.

Guidance, Outlook, and Risks

• Cash Runway: Following the March 17, 2025 amendment to the Janssen Agreement, management projects that current cash levels combined with reduced funding obligations will fund operations into mid-2026.
• Clinical Pipeline: The company is advancing NBTXR3 in head and neck cancer (NANORAY-312 Phase 3) and lung cancer (CONVERGE Phase 2). It is also exploring immuno-oncology combinations (Study 1100) and other indications (pancreatic, esophageal, liver, soft tissue sarcoma).
• Key Risks:
  • Reliance on Janssen: Future profitability depends heavily on Janssen's ability to successfully develop, obtain regulatory approval for, and commercialize NBTXR3.
  • Regulatory Uncertainty: NBTXR3 is classified as a drug in the U.S. and a medical device in the EU, creating a complex regulatory pathway.
  • Capital Requirements: The company has incurred losses since inception and will require additional funding if milestones are not met or if development costs exceed expectations.
  • Internal Controls: The company previously identified material weaknesses in internal controls over financial reporting (2022-2023) but concluded these were remediated as of December 31, 2024.

Important Facts for Investor Verification

• Revenue Recognition: Verify the accounting treatment of the negative €23.4 million revenue adjustment related to the Janssen contract modification and the associated €35.6 million refund liability recorded on the balance sheet.
• Cash Runway Extension: Confirm the specific terms of the March 17, 2025 Janssen amendment regarding the transfer of funding obligations for the NANORAY-312 trial and its impact on future cash burn.
• Debt Covenants: Review the EIB loan terms, specifically the royalty-based interest and the milestone prepayment mechanisms triggered by future financing or commercialization events.
• Clinical Trial Progress: Monitor patient enrollment rates and interim analysis timelines for the NANORAY-312 Phase 3 trial, as delays could impact milestone payments and regulatory approval.
• Internal Control Remediation: Assess the effectiveness of the remediation plan for previously identified material weaknesses in internal controls over financial reporting.